EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Nutritional considerations with antiobesity medications

Jaime P Almandoz iD, Thomas A Wadden iD, Colleen Tewksbury, Caroline M Apovian iD, Angela Fitch, Jamy D Ard iD, Zhaoping Li iD, Jesse Richards iD, W Scott Butsch iD, Irina Jouravskaya, Kadie S Vanderman iD, Lisa M Neff iD

Obesity · 2024-09 · 32 (9) · 1613-1631

DOI: 10.1002/oby.24067 ↗

At a glance

Übersichtsarbeit in Obesity, published online on 2024-06-10. Written by Jaime P Almandoz and 11 co-authors. Institution: Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Anti-Obesity Agents, Obesity. Cited 141 times so far (Crossref); 101 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Eli Lilly and Company.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence‐based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well‐being and promote optimal nutritional and medical outcomes.

Subjects

MeSH terms (MEDLINE)

Anti-Obesity AgentsObesityHumansNutrition AssessmentQuality of LifeNutritional StatusWeight LossDietary FiberExercise

Substances

Anti-Obesity AgentsDietary Fiber

Authors and institutions

  • Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Knownwell, Boston, Massachusetts, USA.
  • Department of Epidemiology and Prevention and Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

ORCID profiles: Jaime P Almandoz, Thomas A Wadden, Caroline M Apovian, Jamy D Ard, Zhaoping Li, Jesse Richards, W Scott Butsch, Kadie S Vanderman, Lisa M Neff

Funding

  • Eli Lilly and Company

Cite

APA

Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., Vanderman, K. S., & Neff, L. M. (2024). Nutritional considerations with antiobesity medications. Obesity, 32(9), 1613-1631. https://doi.org/10.1002/oby.24067

Vancouver

Almandoz JP, Wadden TA, Tewksbury C, Apovian CM, Fitch A, Ard JD, et al. Nutritional considerations with antiobesity medications. Obesity. 2024;32(9):1613-1631. doi:10.1002/oby.24067

BibTeX
@article{Almandoz2024,
  author = {Almandoz, Jaime P and Wadden, Thomas A and Tewksbury, Colleen and Apovian, Caroline M and Fitch, Angela and Ard, Jamy D and Li, Zhaoping and Richards, Jesse and Butsch, W Scott and Jouravskaya, Irina and Vanderman, Kadie S and Neff, Lisa M},
  title = {Nutritional considerations with antiobesity medications},
  journal = {Obesity},
  year = {2024},
  volume = {32},
  number = {9},
  pages = {1613--1631},
  doi = {10.1002/oby.24067}
}
Start for free →